Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486256 | 0.85 | CYP11B1 (0.35) | CYP11B1CYP11B2CYP19A1PDE4APDE4B | |
| SCHEMBL17486280 | 0.82 | HTR2C (0.43) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17486129 | 0.81 | L3MBTL1 (0.40) | PIK3CDL3MBTL1 | |
| SCHEMBL17486164 | 0.79 | PDGFRB (0.33) | L3MBTL1 | |
| SCHEMBL17485976 | 0.77 | DGAT1 (0.45) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL17486132 | 0.76 | ALDH1A1 (0.40) | PIK3CDL3MBTL1 | |
| SCHEMBL17486255 | 0.75 | GRM2 (0.35) | CYP11B1CYP11B2PDE4APDE4BPDE4C | |
| SCHEMBL17485974 | 0.73 | HSD17B1 (0.37) | L3MBTL1 | |
| SCHEMBL17486178 | 0.72 | L3MBTL1 (0.47) | CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL19295129 | 0.71 | CYP11B1 (0.33) | CYP11B1CYP11B2PIK3CDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | CYP11B1 2725/4885CYP11B2 2183/4885CYP19A1 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.